Tysabri PBS submission

New form of Tysabri® under PBAC consideration

MS Australia will be making a submission advocating for the subcutaneous form of Tysabri® to be listed on the PBS, as we welcome affordable access to all treatment options that have been shown in clinical trials to provide safe and effective treatment for MS.

Rohan Greenland The May 50K

From our CEO

CEO Rohan Greenland reflects on the achievements over the past year and looks ahead to MS Australia’s goals for 2023, where our focus will remain tightly on supercharging MS research, advocacy, education and awareness.

New types of clinical trials on the horizon for MS

New types of clinical trials on the horizon for MS

Adaptive clinical trials are new forms of clinical trials that are used to answer complex research questions more efficiently than traditional methods. When used in MS, adaptive clinical trials can deliver more effective therapies to people living with multiple sclerosis sooner, thereby protecting brain health.

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

New form of Tysabri® under PBAC consideration